Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)

Phase 2

Terminated

Conditions: Acute Lymphoblastic Leukemia

Interventions: Biological: Tisagenlecleucel

First Posted Date: 2020-01-13

Last Posted Date: 2023-01-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 5

Registration Number: NCT04225676

Locations: 🇺🇸
Childrens Hospital Los Angeles Divisionof Hematology/Oncology, Los Angeles, California, United States
🇺🇸
Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States

and more 1 locations

Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

Phase 3

Terminated

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: Ligelizumab

First Posted Date: 2019-12-26

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1033

Registration Number: NCT04210843

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam

Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis

Phase 3

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: AIN457 6 mg/kg i.v.
Drug: Placebo
Drug: AIN457 3 mg/kg

First Posted Date: 2019-12-24

Last Posted Date: 2025-05-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 381

Registration Number: NCT04209205

Locations: 🇹🇷
Novartis Investigative Site, Bursa, Gorukle, Turkey

Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

Phase 3

Active, not recruiting

Conditions: Advanced HER2+Breast Cancer

Interventions: Drug: Alpelisib matching Placebo
Drug: Alpelisib
Drug: Trastuzumab
Drug: Pertuzumab

First Posted Date: 2019-12-23

Last Posted Date: 2025-05-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 19

Registration Number: NCT04208178

Locations: 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸
University of California LA, Los Angeles, California, United States
🇪🇸
Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain

Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

Phase 3

Terminated

Conditions: Lupus Nephritis

Interventions: Drug: secukinumab
Drug: Placebo

First Posted Date: 2019-11-29

Last Posted Date: 2025-05-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 275

Registration Number: NCT04181762

Locations: 🇺🇸
University Of Alabama, Birmingham, Alabama, United States
🇺🇸
Kaiser Permanente Fontana, Fontana, California, United States
🇺🇸
University of California LA, Los Angeles, California, United States

and more 6 locations

Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

Phase 3

Active, not recruiting

Conditions: Hidradenitis Suppurativa

Interventions: Drug: secukinumab

First Posted Date: 2019-11-27

Last Posted Date: 2025-05-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 703

Registration Number: NCT04179175

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
🇺🇸
Skin Specialists PC, Omaha, Nebraska, United States
🇺🇸
Icahn School Of Med At Mount Sinai, New York, New York, United States

and more 27 locations

Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Recruiting

Conditions: Spinal Muscular Atrophy (SMA)

Interventions: Other: Prospective observational registry
Drug: Zolgensma

First Posted Date: 2019-11-22

Last Posted Date: 2025-01-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 700

Registration Number: NCT04174157

Locations: 🇬🇷
Penteli Children's Hospital, Penteli, Attikis, Greece
🇬🇷
St. Sophia Children's Hospital, Thessaloniki, Greece
🇯🇵
Nikko Memorial Hospital, Hokkaido, Japan

and more 96 locations

Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy

Phase 2

Completed

Conditions: Cardiomyopathy, Hypertrophic

Interventions: Drug: LCZ696
Drug: Placebo

First Posted Date: 2019-11-15

Last Posted Date: 2025-05-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 46

Registration Number: NCT04164732

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA

Phase 3

Completed

Conditions: Ankylosing Spondylitis

Interventions: Drug: Placebo
Drug: Secukinumab

First Posted Date: 2019-11-07

Last Posted Date: 2024-06-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 527

Registration Number: NCT04156620

Locations: 🇹🇷
Novartis Investigative Site, Istanbul, Turkey

Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL

Phase 2

Withdrawn

Conditions: B-cell Acute Lymphoblastic Leukemia

Interventions: Biological: Tisagenlecleucel

First Posted Date: 2019-11-07

Last Posted Date: 2023-03-09

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04156659

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy